Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

Inclusion Criteria: * Have histologically proven malignant Glioblastoma Multiforme in first or second relapse * Have failed prior Fractionated External Beam Cranial Irradiation or IMRT * Be at least 18 years old and with a life expectancy ≥ 8 weeks or ≥ 4 weeks if failed prior Avastin therapy * Have a Karnofsky performance status of ≥ 60 * Have adequate bone marrow function, liver function, and renal function before starting therapy Exclusion Criteria: * Have had more than two relapses * Have had radiosurgery * Have a cardiac ejection fraction \< 50% by MUGA or ECHO * Have Troponin-I elevated above the normal range * Have an increasing steroid requirement * Have MRI evidence at baseline of enlarging or clinically significant intratumor hemorrhage * Have active stroke and/or transient ischemic attack not optimally managed * Have active cardiovascular disease (e.g. sub-optimally managed angina, impending myocardial infarction, or uncontrolled hypertension) * Be pregnant or breast feeding * Have had prior hypersensitivity reaction to Cremophor EL * Be HIV positive